Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen's Kyprolis Miss In First-Line Myeloma Surprising, But Clinically Irrelevant

Executive Summary

Because CLARION was designed to test Kyprolis head-to-head against fellow proteasome inhibitor Velcade, the failure could hurt the drug's standing in its class. But the trial design used a regimen largely phased out of clinical practice and Amgen has other chances to prove superiority.


Related Content

Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition
3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control
Amgen Plugs Away On Repatha, With Hope For New Monthly Product
Multiple Myeloma Market Snapshot: New Drugs And Big Changes
Another Step Towards Myeloma Market Dominance For Amgen's Kyprolis
Kyprolis ENDEAVOR data signal a changing of the guard for multiple myeloma treatment
Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?


Related Companies